Welcome to Drug and Alcohol Treatment
| ||
Drug Treatment Peripheral Vascular Disease Article
This is a selection made from among articles on Drug Treatment Peripheral Vascular Disease. For a permanent link to this article, or to bookmark it for future reading, click here.
from:
Drug and Alcohol Rehab
By Ken Marlborough
Rehabilitation from drug addiction is a complex process. It involves commitment from the individual addict to abstain from further drug use. The physical dependence on the drug needs to be overcome through medical intervention. Medical supervision is essential to safely detoxify an addicted individual. Safety is an issue since sudden withdrawal of a drug will lead to very profound physiological changes that can be very uncomfortable and can sometimes be life threatening. The range of drugs abused is wide but general principles apply to drug and alcohol rehabilitation.
After the medical detoxification process, which is often in an inpatient setting, a program to continue the rehab process as an outpatient is essential. Sometimes replacement drugs are needed such as methadone maintenance programs where patients are given methadone to replace the heroin that is abused. The methadone helps prevent the euphoria and at the same time decreases the craving that is central to addiction. A typical dose that may work is 30-60 milligrams of methadone daily but this is variable and depends on the intensity of addiction among other factors. Alcohol rehab often involves an acute hospital based detoxification where a thorough medical assessment is done and then drugs belonging to the class called benzodiazepines are given to prevent withdrawal. Medical issues are often the main reason an addict enters a treatment entry point.
After this acute phase an outpatient 12 step program such as Alcoholics Anonymous is critical to maintain abstinence. Many patients who are addicted to drugs have co-morbid psychiatric conditions like depression that need to be addressed. Others have HIV/AIDS, which also need to be managed if a lasting solution is needed. Many rehab programs are covered by insurance and charity. They also have social workers who will help with the practical aspects of getting back to a productive life.
Above all, the commitment of the individuals working in the program helps sustain and develop faith and trust in the system since addicts are often marginalized members of society.
Drug Rehab provides detailed information on Drug Rehab, Drug Rehab Programs, Drug Rehab Centers, Drug And Alcohol Rehab and more. Drug Rehab is affiliated with Drug Detox Rehab.
Article Source: http://EzineArticles.com/?expert=Ken_Marlborough
http://EzineArticles.com/?Drug-and-Alcohol-Rehab&id=231119
Drug Treatment Peripheral Vascular Disease Specific links
Drug Treatment Peripheral Vascular Disease News
Cook Medical Launches First Drug-Eluting Stent in Australia to Treat ... - MarketWatch (press release)
Cook Medical Launches First Drug-Eluting Stent in Australia to Treat ... MarketWatch (press release) BLOOMINGTON, Ind., May 21, 2012 (BUSINESS WIRE) -- Cook Medical, a world leader in minimally invasive medical technologies, has launched a first-of-its-kind drug-eluting peripheral stent in Australia, the Zilver(R) PTX(R) Drug-Eluting Peripheral Stent. |
Boston Scientific Announces FDA Approval and U.S. Launch of EPIC(TM) Vascular ... - MarketWatch (press release)
 Mass High Tech | Boston Scientific Announces FDA Approval and U.S. Launch of EPIC(TM) Vascular ... MarketWatch (press release) "The Epic Stent is another example of our commitment to innovation in treating peripheral vascular disease, a growing worldwide health concern," said Jeff Mirviss, president of the Boston Scientific Peripheral Interventions Division. Boston Scientific's CE Mark and European Launch of Innova FDA Approval for BSX Epic Stent - Analyst Blog |
Global Markets for Coronary Stent Devices - MarketWatch (press release)
Global Markets for Coronary Stent Devices MarketWatch (press release) The study analyzes select coronary stent devices for treating various cardiac diseases such as coronary artery disease, peripheral vascular disease, valvular heart disease, congestive heart failure and many others; understanding the global market from ... |
Boston Scientific Announces CE Mark and European Launch of Innova(TM) Self ... - MarketWatch (press release)
Boston Scientific Announces CE Mark and European Launch of Innova(TM) Self ... MarketWatch (press release) NATICK, Mass., May 14, 2012 /PRNewswire via COMTEX/ -- Boston Scientific Corporation (NYSE:BSX) announces CE Mark and European market launch of the Innova(TM) Self-Expanding Bare-Metal Stent System, which is designed to treat peripheral vascular ... Boston Scientific Announces CE Mark and European Launch of Innova™ Self ... Boston Scientific Innova Has CE Mark |
Boston Scientific gets FDA nod for vascular stent - Boston Business Journal
Boston Scientific gets FDA nod for vascular stent Boston Business Journal (NYSE: BSX) won US Food and Drug Administration approval and immediately launched its Epic Vascular Self-Expanding Stent System, which is designed to open blocked arteries in patients with a form of peripheral vascular disease. Boston Scientific gets FDA nod for medical device sales of new stent system FDA Approval for BSX Epic Stent |
LeMaitre Vascular Q1 2012 Sales $13.9mm (+8% Organic), Op. Profit $0.9mm - MarketWatch (press release)
LeMaitre Vascular Q1 2012 Sales $13.9mm (+8% Organic), Op. Profit $0.9mm MarketWatch (press release) LeMaitre Vascular is a provider of devices for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to ... |
Studies of Medtronic IN.PACT Drug-Eluting Balloons Show Significant Benefit in ... - MarketWatch (press release)
 Angioplasty.Org | Studies of Medtronic IN.PACT Drug-Eluting Balloons Show Significant Benefit in ... MarketWatch (press release) PACT drug-eluting balloon from Medtronic, Inc. (NYSE:MDT) over a corresponding conventional treatment for coronary and peripheral artery disease. Medtronic IN.PACT drug-eluting balloons received CE (Conformite Europeenne) mark in 2008 and 2009 and are ... CORRECTING And REPLACING Medtronic IN.PACT Drug-Eluting Balloon Studies Show ... |
Cardiovascular Systems Announces Pricing of Public Offering of Common Stock - MarketWatch (press release)
Cardiovascular Systems Announces Pricing of Public Offering of Common Stock MarketWatch (press release) PAUL, Minn., May 22, 2012 (BUSINESS WIRE) -- Cardiovascular Systems, Inc. ("CSI") (NASDAQ:CSII) , a medical device company focused on developing and commercializing innovative interventional treatment systems for vascular disease, today announced the ... |
Generic prescription drug for Plavix to cost less - MENAFN.COM
Generic prescription drug for Plavix to cost less MENAFN.COM Plavix has been successfully used for patients with heart disease and heart attacks, those getting stents placed in their heart, stroke and peripheral artery disease, among others. Before Plavix arrived in 1997, aspirin was the standard treatment for ... |
Boston Scientific Innova Has CE Mark - Zacks.com
Boston Scientific Innova Has CE Mark Zacks.com The stent is designed to treat peripheral vascular lesions in arteries above the knee. Mauro Gargiulo, physician at Sant'Orsola-Malpighi in Bologna, Italy considers treatment of arteries above the knee to be difficult. This is because the anatomy of ... |